News Release
![](img/kv.jpg)
2024
-
July 16, 2024
Results of a Japan Phase III Clinical Trial of the GnRH Antagonist Linzagolix in Patients with Uterine Fibroids - Primary Endpoint has been Achieved -
-
June 10, 2024
Licensing Agreement for GnRH Antagonist Linzagolix with JW Pharmaceutical Corporation in Korea
-
March 19, 2024
Notice Concerning Status of Acquisition and Completion of the Company's Own Shares
-
March 1, 2024
Notice Concerning Status of Acquisition of the Company's Own Shares
-
February 1, 2024
Notice Concerning Status of Acquisition of the Company's Own Shares
-
January 4, 2024
Notice Concerning Status of Acquisition of the Company's Own Shares